A Bivalent Omicron-Containing Booster Vaccine Against Covid-19

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2022 Sep 16

PMID 36112399

Authors

Spyros Chalkias

Charles Harper

Keith Vrbicky

Stephen R Walsh

Brandon Essink

Adam Brosz

Nichole McGhee

Joanne E Tomassini

Xing Chen

Ying Chang

Andrea Sutherland

David C Montefiori

Bethany Girard

Darin K Edwards

Jing Feng

Honghong Zhou

Lindsey R Baden

Jacqueline M Miller

Rituparna Das

Affiliations

Soon will be listed here.

Abstract

Background: The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.

Methods: In this ongoing, phase 2-3 study, we compared the 50-μg bivalent vaccine mRNA-1273.214 (25 μg each of ancestral Wuhan-Hu-1 and omicron B.1.1.529 [BA.1] spike messenger RNAs) with the previously authorized 50-μg mRNA-1273 booster. We administered mRNA-1273.214 or mRNA-1273 as a second booster in adults who had previously received a two-dose (100-μg) primary series and first booster (50-μg) dose of mRNA-1273 (≥3 months earlier). The primary objectives were to assess the safety, reactogenicity, and immunogenicity of mRNA-1273.214 at 28 days after the booster dose.

Results: Interim results are presented. Sequential groups of participants received 50 μg of mRNA-1273.214 (437 participants) or mRNA-1273 (377 participants) as a second booster dose. The median time between the first and second boosters was similar for mRNA-1273.214 (136 days) and mRNA-1273 (134 days). In participants with no previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the geometric mean titers of neutralizing antibodies against the omicron BA.1 variant were 2372.4 (95% confidence interval [CI], 2070.6 to 2718.2) after receipt of the mRNA-1273.214 booster and 1473.5 (95% CI, 1270.8 to 1708.4) after receipt of the mRNA-1273 booster. In addition, 50-μg mRNA-1273.214 and 50-μg mRNA-1273 elicited geometric mean titers of 727.4 (95% CI, 632.8 to 836.1) and 492.1 (95% CI, 431.1 to 561.9), respectively, against omicron BA.4 and BA.5 (BA.4/5), and the mRNA-1273.214 booster also elicited higher binding antibody responses against multiple other variants (alpha, beta, gamma, and delta) than the mRNA-1273 booster. Safety and reactogenicity were similar with the two booster vaccines. Vaccine effectiveness was not assessed in this study; in an exploratory analysis, SARS-CoV-2 infection occurred in 11 participants after the mRNA-1273.214 booster and in 9 participants after the mRNA-1273 booster.

Conclusions: The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns. (Funded by Moderna; ClinicalTrials.gov number, NCT04927065.).

Citing Articles

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age.

Omole T, Pelayo E, Weinberg A, Chalkias S, Endale Z, Tamms G Vaccines (Basel). 2025; 13(2).

PMID: 40006738 PMC: 11860627. DOI: 10.3390/vaccines13020192.

A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching.

Lee J, Sachithanandham J, Lee J, Shapiro J, Li M, Sitaris I Microbiol Spectr. 2025; 13(3):e0219024.

PMID: 39887251 PMC: 11878001. DOI: 10.1128/spectrum.02190-24.

Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients.

Tometten I, Brandt T, Schlotz M, Stumpf R, Landmann S, Kantauskaite M Front Immunol. 2025; 15:1476294.

PMID: 39877366 PMC: 11772199. DOI: 10.3389/fimmu.2024.1476294.

An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.

Mambelli F, de Araujo A, Farias J, de Andrade K, Ferreira L, Minoprio P Pathogens. 2025; 14(1).

PMID: 39860984 PMC: 11768231. DOI: 10.3390/pathogens14010023.

Immunobridging Trials: An Important Tool to Protect Vulnerable and Immunocompromised Patients Against Evolving Pathogens.

Cruz P, Lam J, Abdalla J, Bell S, Bytyci J, Brosh-Nissimov T Vaccines (Basel). 2025; 13(1).

PMID: 39852798 PMC: 11768488. DOI: 10.3390/vaccines13010019.

References

Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S . Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10.... MMWR Morb Mortal Wkly Rep. 2022; 71(7):255-263. PMC: 8853475. DOI: 10.15585/mmwr.mm7107e2. View

Suryawanshi R, Chen I, Ma T, Syed A, Brazer N, Saldhi P . Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature. 2022; 607(7918):351-355. PMC: 9279157. DOI: 10.1038/s41586-022-04865-0. View

Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View

Pulliam J, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome M . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022; 376(6593):eabn4947. PMC: 8995029. DOI: 10.1126/science.abn4947. View

B Gilbert P, Montefiori D, McDermott A, Fong Y, Benkeser D, Deng W . Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021; 375(6576):43-50. PMC: 9017870. DOI: 10.1126/science.abm3425. View

Gaebler C, Wang Z, Lorenzi J, Muecksch F, Finkin S, Tokuyama M . Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591(7851):639-644. PMC: 8221082. DOI: 10.1038/s41586-021-03207-w. View

Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

El Sahly H, Baden L, Essink B, Doblecki-Lewis S, Martin J, Anderson E . Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021; 385(19):1774-1785. PMC: 8482810. DOI: 10.1056/NEJMoa2113017. View

Tang J, Novak T, Hecker J, Grubbs G, Zahra F, Bellusci L . Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022; 13(1):2979. PMC: 9142524. DOI: 10.1038/s41467-022-30649-1. View

10.

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

11.

Tseng H, Ackerson B, Luo Y, Sy L, Talarico C, Tian Y . Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022; 28(5):1063-1071. PMC: 9117141. DOI: 10.1038/s41591-022-01753-y. View

12.

Prasad N, Derado G, Nanduri S, Reses H, Dubendris H, Wong E . Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(18):633-637. PMC: 9098239. DOI: 10.15585/mmwr.mm7118a4. View

13.

Pajon R, Doria-Rose N, Shen X, Schmidt S, ODell S, McDanal C . SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. N Engl J Med. 2022; 386(11):1088-1091. PMC: 8809504. DOI: 10.1056/NEJMc2119912. View

14.

Chalkias S, Eder F, Essink B, Khetan S, Nestorova B, Feng J . Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022; 28(11):2388-2397. PMC: 9671805. DOI: 10.1038/s41591-022-02031-7. View

15.

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

16.

Chu L, Vrbicky K, Montefiori D, Huang W, Nestorova B, Chang Y . Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022; 28(5):1042-1049. PMC: 9117133. DOI: 10.1038/s41591-022-01739-w. View

17.

OConnell S, Anderson E, Jackson L, Luke C, Nason M, Roederer M . Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021; 373(6561):1372-1377. PMC: 8691522. DOI: 10.1126/science.abj4176. View